Exact Sciences Corporation (EXAS)
NEUTRALFondamental
39
Prix
$-
Capitalisation boursière
$20.03B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$3.25B
Exercice clos le 31/12/2025
Résultat net
$-208M
Exercice clos le 31/12/2025
Flux de trésorerie libre
$282M
Capitaux propres totaux
$2.40B
Passif total
$2.53B
Ratio de liquidité général
2.43
Couverture des intérêts
-
Dette/EBITDA
35.47
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$76.95
Prix actuel
-
Marge de sécurité
-
Fourchette de juste valeur
$50.02 - $103.88
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
-
ROE
-8.7%
Ratio P/B
8.34
P/FCF
-
Marge brute
69.7%
ROIC
-4.8%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
-4.8%
WACC
7.1%
ROIC − WACC
-11.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (7)
- Price CAGR 22.89%
- Gross Margin 69.7%
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 16.8%
- Net Margin Trend -6.4% vs -37.3%
Échoué (9)
- ROIC -4.8%
- P/B Ratio 8.34
- CapEx intensity
- Debt/EBITDA
- DCF valuation (Unknown)
- ROE -8.5%
- Analyst Consensus 28% Buy
- Earnings Surprise avg -111.7%
- Piotroski F-Score 2/9
Indisponible (11)
- EPS data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
Score F de Piotroski
Préoccupations financières sérieuses
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Gouvernance
Risque d'audit
1
Risque du conseil
2
Risque de rémunération
3
Risque droits des actionnaires
4
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for EXAS, sourced from Markets Gazette.
- 2/23/2026POSITIVEAbbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal
Abbott Laboratories is launching a significant bond sale, in as many as eight parts, to fund its approximately $21 billion acquisition of cancer-screening company Exact Sciences Corp. This move signals Abbott's strong commitment to finalizing a strategic deal that will bolster its diagnostics portfolio. For shareholders of Exact Sciences, this development is a clear positive catalyst. Acquisitions of this magnitude are typically executed at a premium to the target's current market price, suggesting an immediate upward revaluation of the stock. Abbott's financing action validates the technology and growth potential of Exact Sciences, turning the company's intrinsic value into a tangible gain for investors as the deal progresses.
via Markets Gazette